Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

AstraZeneca : says COVID-19 vaccine trial in U.S still on hold

share with twitter share with LinkedIn share with facebook
09/19/2020 | 11:38pm EDT
FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the NYSE in New York

AstraZeneca Plc said on Saturday that its COVID-19 vaccine trial in the United States is still on hold.

AstraZeneca on Saturday published a document https://bit.ly/2FNcqu7 describing details of how the COVID-19 vaccine trial was being carried out, which was first reported by the New York Times.

(Reporting by Rama Venkat in Bengaluru; Editing by Michael Perry)


Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -1.40% 7766 Delayed Quote.2.09%
THE NEW YORK TIMES COMPANY -1.15% 39.66 Delayed Quote.23.28%
share with twitter share with LinkedIn share with facebook
All news about ASTRAZENECA PLC
10/30SINOVAC BIOTECH : Brazil will buy China COVID-19 vaccine, VP Mourão says, contra..
RE
10/30THE LATEST : U.S. COVID-19 cases surge past 9 million
AQ
10/30Lonza to make COVID-19 antibody combination for AstraZeneca
RE
10/30Pfizer, Astra Vaccine With Oxford Under Accelerated UK Reviews- Bloomberg Ne..
RE
10/30ASTRAZENECA : sells commercial rights to two drugs in $400 million deal
RE
10/30ASTRAZENECA : Atacand to be divested to Cheplapharm in more than 70 countries
AQ
10/30ASTRAZENECA : to Sell Atacand Rights in Around 70 Countries for $400 Million
DJ
10/30BioNTech CEO expects data from late-stage study soon
RE
10/30LONZA : to make COVID-19 antibody combination for AstraZeneca
RE
10/29EU to fund transfer of COVID-19 patients across borders to prevent hospitals ..
RE
More news
Financials (USD)
Sales 2020 26 659 M - -
Net income 2020 3 027 M - -
Net Debt 2020 13 202 M - -
P/E ratio 2020 46,6x
Yield 2020 2,80%
Capitalization 132 B 132 B -
EV / Sales 2020 5,45x
EV / Sales 2021 4,75x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 118,34 $
Last Close Price 100,57 $
Spread / Highest target 54,6%
Spread / Average Target 17,7%
Spread / Lowest Target -34,4%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC2.09%132 036
JOHNSON & JOHNSON-6.01%361 159
ROCHE HOLDING AG-6.13%275 049
PFIZER INC.-9.44%196 047
MERCK & CO., INC.-17.31%191 944
NOVARTIS AG-22.21%177 493